Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Tumor burden and disease status were not correlated with CRS risk or severity in newly diagnosed, relapsed/refractory myeloma managed with elranatamab.